Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICT-HCT Study
NCT01812252Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2013
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Fred Hutchinson Cancer Center. Started Aug 2013; status: completed.
02
Drugs
decitabineazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01812252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812252.